August 2023

Carbon Engineering has been acquired by Occidental Petroleum (NYSE: OXY) in a $1.1B all cash transaction.

September 2022

Bango (AIM:BGO) announced the acquisition of Docomo Digital – the global payments business of NTT DOCOMO – bringing an additional $3.5B of end user spend from c.2 billion users worldwide.

April 2021

Phico Therapeutics awarded up to $18.2 million (c.£13.2 million) CARB-X funding to advance SASPject antibacterial therapy through Phase 1 clinical trials.

April 2021

FDA approves first ADC Therapeutics anti-cancer drug, ZYNLONTA™, for clinical use in patients with relapsed or refractory diffuse large B-Cell Lymphoma.

March 2021

ET Capital, in collaboration with Carbon13 – the venture builder for the climate emergency, has launched the first of a series of SEIS funds investing in new businesses focused on signficant carbon emission reduction.

May 2020

ADC Therapeutics SA, the innovative anti-cancer therapeutics business, has floated on the New York Stock Exchange. Demand for the issue was high with an upsized placing and shares trading at an immediate premium.

January 2020

ADC Therapuetics announces positive results from pivotal Phase 2 clinical trial of its lead therapeutic.

August 2019

BBC features the life transforming impact of Oxsight Crystal smart glasses for a patient with Usher’s disease.

November 2018

ADC Therapeutics Announces First Patients Dosed in Phase I/II Clinical Trial of ADCT-602 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

August 2018

Phico Therapeutics awarded Innovate UK funding for £1.4 million ($1.87M) antibacterial therapy project.